Veloxis Pharmaceuticals Announces Financial Calendar for 2019

Udgivet den 28-12-2018  |  kl. 22:12  |  

Company Release no. 23/2018

To: NASDAQ Copenhagen A/S                                                             

Copenhagen, Denmark, 28 December 2018


Veloxis Pharmaceuticals Announces Financial Calendar for 2019


Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2019. 

The full updated calendar is shown below.


19 February 2019:      Deadline for Veloxis's Receipt of Shareholder Proposals for the 2019 Annual General Meeting. 
27 February 2019:    Release of 2018 Annual Report.
3 April 2019:    2019 Annual General Meeting.
6 May 2019:    Q1 Interim Report - for the period 1 January to 31 March, 2019.
8 August 2019:    Q2 Interim Report - for the period 1 January to 30 June, 2019.
12 November 2019:    Q3 Interim Report - for the period 1 January to 30 September, 2019.

       

For more information, please contact:

Craig A. Collard
President & CEO
Phone: +1 919 591 3090
Email: cac@veloxis.com 
Ira Duarte
CFO
Phone: +1 919 591 3090
Email: idu@veloxis.com


About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

For further information, please visit www.veloxis.com.

Attachment

Veloxis Financial Calendar Release 23 - 28 Dec 2018

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

09:36 Tyske indkøbschefer ser endnu mere negativt på aktiviteten i september end ventet
09:25 Berenberg hæver Novonesis-kursmål med næsten 20 pct. til 530 kr.
09:23 Aktier/åbning: C25 siver fra åbningen trods fremdrift i Novo Nordisk
09:17 Danske Bank skruer op for Sampos kursmål efter køb af Topdanmark
08:45 Obligationer/åbning: Lille rentefald inden nøgletal på stribe
08:28 Aktier/tendens: Let positiv start i sigte med Novo som joker
08:25 Stigende håb i Kina om økonomisk redningsplanke efter lavere rente
08:20 HSBC ramt af seksdobling af misligholdte erhvervsejendomslån i Hongkong
07:27 Coloplast skal forsøge at komme sig oven på formands storudsalg i sidste uge
07:12 Råvarer: Oliepriserne starter ugen med en stigning efter øgede spændinger i Mellemøsten
07:08 Obligationer/tendens: Stille åbning i sigte inden stribevis af nøgletal
06:46 Jefferies indleder dækning af FLS med en købsanbefaling
06:43 Asien: Positive strømninger fortsætter på japansk lukkedag
06:35 USA's toppolitikere laver aftale og undgår nedlukning før valget
06:35 Goldman Sachs ser S&P 500 passere indeks 6000 inden årets udgang
06:32 Asien: Positive strømninger fortsætter på japansk lukkedag
06:32 Valuta: Bitcoin svajer i ellers stagneret valutamarked under japansk fravær
06:32 USA/T-bond: Lange renter steg igen på let negativ fredag
06:32 USA/lukning: Fedex blev banket i bund efter kæmpe skuffelse - Dow Jones holdt rekordkursen
06:30 Kalender med link - mandag den 23. september